hu14.18-IL2
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for hu14.18-IL2, covering 2019-10-22 to 2019-10-22. Get the full timeline:
Most recent: Clinical Trial Update: Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma [Phase 2]